Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company developing wholly-owned drug candidates to treat neurological diseases, pain, cancer, and metabolic disorders, using its POZ platform, a proprietary polyoxazoline polymer technology that enables controlled drug loading and release and attachment of small molecules, proteins, peptides, and DNA to modify pharmacokinetic profiles. The company’s pipeline includes SER-214 for Parkinson’s disease and restless legs syndrome, SER-226 for postoperative pain, SER-228 for refractory epilepsy, and SER-232 for chemotherapy-induced nausea and vomiting, among other POZ-based delivery programs. The POZ platform aims to improve safety and efficacy by achieving favorable pharmacokinetics compared with traditional polymers and broadens the range of compounds that can be effectively delivered. Serina Therapeutics was founded in 2006 and is based in Huntsville, Alabama.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.